查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1961135

基因編輯市場－全球產業規模、佔有率、趨勢、機會和預測：按產品/服務、技術、應用、最終用戶、地區和競爭格局分類，2021-2031年

Gene Editing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product & Service, By Technology, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球基因編輯市場預計將從 2025 年的 70.8 億美元大幅成長至 2031 年的 132.3 億美元，複合年成長率為 10.98%。

此領域利用生物技術對生物體的遺傳密碼進行精確操控，例如在特定位置進行插入、刪除和修飾。推動此領域發展的主要因素是先天性遺傳疾病發生率的上升，以及CRISPR-Cas9等技術在非癌症治療領域（包括罕見疾病）的拓展。這種強勁的發展勢頭在業界的活躍活動中可見一斑。根據美國基因與細胞治療學會（ASGCT）統計，截至2024年第一季，全球有超過4000種基因、細胞和RNA療法正在開發平臺中，這凸顯了該領域正迅速從實驗研究轉向潛在的臨床應用。

市場概覽
預測期 2027-2031
市場規模：2025年 70.8億美元
市場規模：2031年 132.3億美元
複合年成長率：2026-2031年 10.98%
成長最快的細分市場 脆皮
最大的市場 北美洲

儘管取得了這些進展，但市場仍面臨著與可擴展的治療級載體生產高成本和製程複雜相關的重大障礙。為確保安全性和有效性所需的複雜生產流程造成了巨大的財務障礙，可能限制商業性可行性和病患取得途徑。此外，針對脫靶效應和長期安全性數據的嚴格法律規範可能會延長核准時間，減緩這些創新治療方法進入商業市場的速度。

市場促進因素

CRISPR 和下一代基因編輯技術的進步正在從根本上改變全球基因編輯市場，使其從實驗科學走向商業性現實。這些精準的基因組工具從實驗室成功研發並獲得監管部門核准，即時需要專門的基礎設施來驗證其臨床價值並確保患者能夠獲得治療。擴大這些營運規模對於複雜治療方法的商業性成功至關重要，尤其是那些需要嚴格身份驗證通訊協定的體外治療。 Vertex Pharmaceuticals 就展現了這項進展。根據 Fierce Pharma 報道，到 2024 年 8 月，該公司將在全球運作超過 35 家獲得許可的治療中心，用於開展新核准的CRISPR 療法。此類基礎設施對於消除先進基因藥物交付的物流障礙以及促進其在臨床環境中的更廣泛應用至關重要。

同時，策略聯盟的增加正在推動創新，它將大型製藥企業的大規模資本與新興生物技術公司的專業平台結合。此類合作對於克服高成本以及快速將鹼基編輯和先導編輯等​​新型基因編輯技術轉化為候選療法至關重要。一個典型的例子是Regeneron Pharmaceuticals和Mammoth Biosciences於2024年4月達成的合作（Labiotech報告），其中包括1億美元的預付款，用於開發體內CRISPR療法。此舉標誌著該產業正朝著由雄厚資金支持的下一代遞送系統進行策略轉型。例如，Biospace在2024年8月報告稱，CRISPR Therapeutics持有約19億美元的現金和有價證券，凸顯了其為未來市場成長提供的充足資源。

市場挑戰

全球基因編輯市場的主要障礙在於生產可擴展的治療性載體所需的高昂成本和技術難題。病毒載體的生產需要複雜的生物程序，且必須滿足嚴格的安全性和有效性標準，這往往導致產量低、營運成本過高。這些生產難題成為瓶頸，阻礙了高效的規模化生產，迫使企業採取不永續的定價策略來收回研發投資。因此，高昂的生產成本推高了市場價格，使其達到過高的水平，直接限制了患者的合格，降低了產品的普及率，從而限制了商業性可行性。

這些財務障礙已在報銷和市場進入方面造成了重大困難。這種經濟壓力導致保險公司和支付方不願承擔高昂的治療費用，減緩了市場滲透。據再生醫學聯盟稱，到2024年，新核准基因療法的批發採購成本將達到每位患者310萬美元的峰值，凸顯了這些複雜生產需求帶來的沉重經濟負擔。在生產流程變得更加經濟高效之前，治療潛力和經濟可行性之間的差距將繼續阻礙市場發展向更廣泛的商業性領域擴展。

市場趨勢

將人工智慧 (AI) 整合到引導 RNA 設計中，正在革新藥物研發流程，加速設計出超越天​​然變異能力的蛋白質。這些計算模型能夠預測脫靶交互作用，並比人工實驗方法更快最佳化結合特異性，從而縮短開發週期，提高基因編輯工具的準確性。Start-UpsProfluent 正在展示這項技術進步。根據 Fierce Biotech 2024 年 4 月的一篇報導報道，“Profluent 將 LLM 和 CRISPR 相結合，打造開源 AI 基因編輯計畫”，該公司成功資金籌措了3500 萬美元，用於擴展其旨在創建個性化基因編輯工具的生成式 AI 模型。

同時，基因編輯技術在農業和糧食安全領域的應用日益廣泛，顯示市場正朝著多元化方向發展，而這主要源自於對氣候適應型糧食系統的需求。這一趨勢旨在利用精準的基因組編輯技術，開發出具有更強抗病性和更長保存期限等改良特性的作物，從而規避與基因改造生物相關的複雜監管規定。 AgFunderNews在2024年8月發布的報告《農業基因編輯投資呈現產業復甦跡象》中指出，支持這一發展趨勢的是，該領域的Start-Ups在今年上半年資金籌措了超過1.61億美元的資金。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球基因編輯市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品/服務（試劑/耗材、系統、軟體）分類
    • 依技術（CRISPR、TALEN、ZFN、反義寡核苷酸）
    • 依應用領域（細胞株設計、基因工程、藥物發現）
    • 依最終用戶（製藥公司、生技公司、合約研究組織）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美基因編輯市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲基因編輯市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區基因編輯市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲基因編輯市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲基因編輯市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球基因編輯市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • CRISPR Therapeutics AG
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • GenScript Biotech Corporation
  • Agilent Technologies, Inc.
  • PerkinElmer Inc.
  • Lonza Group Ltd.
  • Tecan Trading AG
  • Sangamo Therapeutics, Inc.
  • Editas Medicine, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23694

The Global Gene Editing Market is projected to expand significantly, rising from USD 7.08 Billion in 2025 to USD 13.23 Billion by 2031, reflecting a compound annual growth rate of 10.98%. This sector involves biotechnological techniques that allow for specific alterations-such as insertions, deletions, or modifications-to an organism's genetic code at precise locations. Growth is largely propelled by the increasing incidence of congenital genetic conditions and the broadening scope of technologies like CRISPR-Cas9 into therapeutic realms beyond cancer, including rare diseases. This strong momentum is evidenced by substantial industry activity; the American Society of Gene & Cell Therapy noted that in the first quarter of 2024, the global development pipeline contained over 4,000 gene, cell, and RNA therapies, highlighting the rapid shift from experimental research to potential clinical applications.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 7.08 Billion
Market Size 2031USD 13.23 Billion
CAGR 2026-203110.98%
Fastest Growing SegmentCRISPER
Largest MarketNorth America

Despite these advancements, the market encounters notable obstacles related to the high expense and complexity involved in manufacturing scalable, therapeutic-grade vectors. The sophisticated production processes necessary to guarantee safety and efficacy create significant financial hurdles, which can restrict commercial viability and patient access. Additionally, rigorous regulatory oversight concerning off-target effects and long-term safety data may extend approval timelines, thereby slowing the pace at which these innovative therapies reach the commercial market.

Market Driver

Progress in CRISPR and next-generation editing technologies is fundamentally transforming the Global Gene Editing Market, moving it from experimental science to commercial reality. The successful advancement of these precise genomic tools from labs to regulatory approval has confirmed their clinical value, creating an immediate need for specialized infrastructure to ensure patient access. Scaling these operations is essential for the commercial success of complex treatments, particularly ex vivo therapies that require strict chain-of-identity protocols. This development is exemplified by Vertex Pharmaceuticals, which, according to Fierce Pharma, had activated over 35 authorized treatment centers worldwide by August 2024 to administer its newly approved CRISPR therapy. Such infrastructure is crucial for removing logistical barriers to delivering advanced genetic medicines, thereby facilitating their wider adoption in clinical practice.

Concurrently, an increase in strategic alliances is driving innovation by merging the substantial capital of major pharmaceutical companies with the specialized platforms of emerging biotech entities. These collaborations are vital for surmounting the high costs of R&D and speeding up the translation of new editing methods, such as base and prime editing, into therapeutic candidates. A prime example occurred in April 2024, when Regeneron Pharmaceuticals partnered with Mammoth Biosciences, as reported by Labiotech, involving a $100 million upfront payment to develop in vivo CRISPR-based therapies. This move signals the industry's strategic shift toward next-generation delivery systems, supported by strong financial backing; for instance, BioSpace reported in August 2024 that CRISPR Therapeutics held approximately $1.9 billion in cash and securities, highlighting the resources available for future market growth.

Market Challenge

A major hurdle restraining the Global Gene Editing Market is the substantial cost and technical difficulty involved in producing scalable, therapeutic-grade vectors. The creation of viral vectors demands complex bioprocesses to meet rigorous safety and efficacy standards, often leading to low yields and excessive operational costs. These manufacturing challenges create bottlenecks that hinder efficient scaling, compelling companies to adopt unsustainable pricing strategies to recoup development investments. Consequently, high production costs result in prohibitive market prices, which directly limit commercial viability by restricting patient eligibility and reducing adoption rates.

The consequences of these financial obstacles are manifest in the difficulties regarding reimbursement and market access. This economic pressure causes tension with insurance providers and payers who are reluctant to fund such costly treatments, thereby retarding market penetration. According to the Alliance for Regenerative Medicine, the wholesale acquisition cost for newly approved gene therapies peaked at $3.1 million per patient in 2024, underscoring the intense economic burden associated with these complex production needs. Until manufacturing processes become more cost-effective, the gap between therapeutic potential and economic practicality will continue to impede the market's expansion into a broader commercial landscape.

Market Trends

The incorporation of Artificial Intelligence into Guide RNA design is revolutionizing the discovery pipeline by facilitating the engineering of proteins that surpass natural variants in capability. These computational models can predict off-target interactions and optimize binding specificity much faster than manual experimental techniques, thereby shortening development timelines and enhancing the precision of editing tools. This technological evolution is illustrated by Profluent, a startup that, according to the Fierce Biotech article 'Profluent combines LLMs and CRISPR for open-source AI gene editing project' from April 2024, secured $35 million to expand its generative AI models aimed at creating bespoke gene editors.

In parallel, the broadening of gene editing applications into agriculture and food security marks a diversification of the market beyond human therapeutics, spurred by the necessity for climate-resilient food systems. This trend targets the development of crops with enhanced traits, such as disease resistance and longer shelf lives, using precise genomic modifications that frequently avoid the complicated regulations associated with transgenic organisms. Confirming this sector's expansion, AgFunderNews reported in August 2024, in their 'Agriculture gene editing investments hint at sector recovery' report, that startups in this specific vertical attracted over $161 million in funding during the first half of the year.

Key Market Players

  • CRISPR Therapeutics AG
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • GenScript Biotech Corporation
  • Agilent Technologies, Inc.
  • PerkinElmer Inc.
  • Lonza Group Ltd.
  • Tecan Trading AG
  • Sangamo Therapeutics, Inc.
  • Editas Medicine, Inc.

Report Scope

In this report, the Global Gene Editing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Editing Market, By Product & Service

  • Reagents & consumables
  • Systems
  • Software

Gene Editing Market, By Technology

  • CRISPER
  • TALEN
  • ZFN
  • Antisense

Gene Editing Market, By Application

  • Cell Line Engineering
  • Genetic Engineering
  • Drug discovery

Gene Editing Market, By End User

  • Pharma
  • Biotech
  • CROs

Gene Editing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Editing Market.

Available Customizations:

Global Gene Editing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gene Editing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product & Service (Reagents & consumables, Systems, Software)
    • 5.2.2. By Technology (CRISPER, TALEN, ZFN, Antisense)
    • 5.2.3. By Application (Cell Line Engineering, Genetic Engineering, Drug discovery)
    • 5.2.4. By End User (Pharma, Biotech, CROs)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Gene Editing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product & Service
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Gene Editing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product & Service
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Gene Editing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product & Service
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Gene Editing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product & Service
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe Gene Editing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product & Service
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Gene Editing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product & Service
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. France Gene Editing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product & Service
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Gene Editing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product & Service
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Gene Editing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product & Service
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Gene Editing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product & Service
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia Pacific Gene Editing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product & Service
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Gene Editing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product & Service
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India Gene Editing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product & Service
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Gene Editing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product & Service
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Gene Editing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product & Service
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Gene Editing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product & Service
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. Middle East & Africa Gene Editing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product & Service
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Gene Editing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product & Service
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Gene Editing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product & Service
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Gene Editing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product & Service
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. South America Gene Editing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product & Service
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Gene Editing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product & Service
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Gene Editing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product & Service
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Gene Editing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product & Service
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Gene Editing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. CRISPR Therapeutics AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Merck KGaA
  • 15.3. Thermo Fisher Scientific, Inc.
  • 15.4. GenScript Biotech Corporation
  • 15.5. Agilent Technologies, Inc.
  • 15.6. PerkinElmer Inc.
  • 15.7. Lonza Group Ltd.
  • 15.8. Tecan Trading AG
  • 15.9. Sangamo Therapeutics, Inc.
  • 15.10. Editas Medicine, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer